07Nov 2024
Faricimab Extends Treatment Interval and reduces Retinal Fluid in Resistant Eye Conditions

Faricimab Extends Treatment Interval and reduces Retinal Fluid in Resistant Eye Conditions

Switching to intravitreal faricimab injections (IFIs) in patients with treatment-resistant neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) showed significant clinical benefits in a treat-and-extend protocol. The treatment interval extended from an average of 37.6 ± 10.8 days to 45.2 ± 16.6 days (p = 0.0016). Spectral-domain OCT results revealed a 35% fluid-free rate among patients, with a significant reduction in central subfield thickness from 327.2 ± 89.1 μm to 294.8 ± 86.5 μm (p = 0.0294). However, no notable differences were observed in best-corrected visual acuity, intraocular pressure, pigment epithelium detachment presence or height.

  • #ophthalmology

Like

Save

Share